Peroxitech Therapeutics
Philadelphia
About Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company developing PIP-2 to reverse acute lung injury (ALI) by targeting the cytokine storm cascade process.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $25.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2022)
- Website: peroxitech.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/peroxitech-therapeutics-16941 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.